Ratnakar Securities Pvt. Ltd.

CONCORD BIOTECH LTD.

NSE : CONCORDBIOBSE : 543960ISIN CODE : INE338H01029Industry : Pharmaceuticals & DrugsHouse : Private

BSE2258.2072.85 (+3.33 %)

PREV CLOSE ( ) 2185.35

OPEN PRICE ( ) 2185.35

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 26732

TODAY'S LOW / HIGH ( )2143.10 2295.00

52 WK LOW / HIGH ( )956.85 2337.25

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984

Management Info

Sudhir Vaid - Chairman Sudhir Vaid - Managing Director

Registered Office

Address 1482-1486 ,Trasad Road,Dholka,
Ahmedabad Dist,
Gujarat-382225

Phone 02714-222604 / 398200

Email complianceofficer@concordbiotech.com

Website www.concordbiotech.com

Registrars Details

Link Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

30Aug Concord Biotec informs about investor
Pursuant to the relevant provisions of SEBI (Listing Obligations and Dis..

02Jul Concord Biotech informs about voting r
Pursuant to Regulation 44(3) of SEBI LODR 2015, Concord Biotech has info..

01Jul Concord Biotech informs about annual r
Pursuant to Regulation 34 of Listing Regulations, Concord Biotech has in..

06Jun Health Product Regulatory Authority is
Health Product Regulatory Authority of Ireland has issued EUGMP certific..

04Jun Concord Biotech informs about earnings
Concord Biotech has informed that in continuation of letter dated May 28..

Financials

in Millions

	QTR Jun 24	ANNUAL 24
Net Profit	582.39	3047.31
Gross Profit	781.67	4091.93
Operating Profit	915.86	4653.37
Net Sales	2158.02	10169.39

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 27963.25 (0.60%)	M.Cap ( in Cr)59419.95
Ajanta Pharma (BSE) 3204.60 (2.61%)	M.Cap ( in Cr)40029.33
Wockhardt (BSE) 1004.45 (5.00%)	M.Cap ( in Cr)15409.22
Alkem Laboratories (BSE) 6138.30 (0.77%)	M.Cap ( in Cr)73392.58
Sanofi India (BSE) 7182.50 (0.55%)	M.Cap ( in Cr)16541.74

Shareholding Pattern

	MUTUAL FUNDS/UTI	5.26%
	PROMOTERS	44.08%
	FI/BANKS/INSURANCE	4.53%
	NON-INSTITUTION	38.46%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
DSP Healthcare Fund...	3.90
Edelweiss Recently ...	3.60
Baroda BNP Paribas ...	2.39
Invesco India Multi...	1.79
Invesco India Aggre...	1.73
Invesco India Flexi...	1.41

attention investors
kyc
ipo
ibt trading
KYC & KRA Status Awareness

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

CONCORD BIOTECH LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES